New paper from Catapano and Carbone groups

news on 24 May , 2019
The study published in Cell Metabolism reveals new way to eliminate cancer stem cells in prostate cancer and enhance treatment efficacy. The study conducted by investigators in the Catapano and Carbone groups at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) in Bellinzona, Switzerland, finds a new way to eliminate cancer stem cells in prostate ca...

Two new papers by Prof. Francesco Bertoni’s lab

news on 20 May , 2019
The research team led by Prof. Francesco Bertoni has recently added information on our knowledge of two hematological malignancies: MALT Lymphoma and Peripheral T-cell lymphoma. The results have been published in Haematologica and Modern Pathology, respectively. Using high-throughput sequencing techniques (DNA copy number analysis, targeted DNA sequencing, DNA methylation and RNA-sequencing), D...

First Castelgrande Lecture, Prof. Douglas Hanahan

news on 15 Apr , 2019
The IOR is pride to welcome Douglas Hanahan, Professor at the Swiss Federal Institute of Technology of Lausanne and Director of the Swiss Institute for Experimental Cancer Research (ISREC) to the first Castelgrande Lecture. With his lecture "“Hallmarks of Cancer: Thinking globally about new cancer therapies” Prof. Hanahan will discuss the challenges that future generations will have to face in ...

Sarah Natalia Mapelli awarded PhD

news on 7 Mar , 2019
Sarah Natalia Mapelli, computational researcher in the Tumor Biology and Experimental Therapeutics group, successfully defended her PhD on January 29th 2019, at Università della Svizzera Italiana (USI) within the SIB PhD training network. She presented her work "Deciphering the complexity of human noncoding promoter-proximal transcriptome: different scales of transcriptional control", derived from...

A new publication by Dr Francesco Bertoni LAB

news on 25 Feb , 2019
Antibody-drug conjugates (ADCs) are an effect therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. A paper now published in Haematologica presents the novel anti-CD19 ADC huB4-DGN462, developed by Colleagues from Immunogen and characterized for its anti-lymphoma activity in Bertoni’s lab. As shown by the work of Chiara Tarantelli and her Colle...

IOR is proud to present his latest Group Leader

news on 18 Feb , 2019
The Institute of Oncology Research is proud to announce the designation of a new Group Leader: Dr. Arianna Calcinotto. Dr. Calcinotto obtained a PhD in Molecular Medicine with honors (Università Vita-Salute San Raffaele, Milan, IT) in 2015. During her PhD she spent a period in the laboratory of Leif Bergsagel (Mayo Clinic, Scottsdale, AZ, US). During these years, she has developed an ext...